How do the two approaches to treating high-risk smoldering multiple myeloma (HRSMM) patients differ?

 

In this week’s video, Dr. Brian G.M. Durie compares two trials that treat high-risk smoldering multiple myeloma — the CESAR trial and the CENTAURUS trial.

BOTTOM LINE:

The IMF’s Black Swan Research Initiative is excited about the CESAR trial and will conduct future trials in hopes of achieving a cure for myeloma.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org